{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T04:47:03Z","timestamp":1784609223286,"version":"3.55.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T00:00:00Z","timestamp":1777766400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"DOI":"10.1186\/s12933-026-03185-1","type":"journal-article","created":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T04:53:24Z","timestamp":1777784004000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The role of bempedoic acid in the management of dyslipidaemia in people with diabetes: an expert opinion of Italian diabetologists"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4989-5194","authenticated-orcid":false,"given":"Massimo","family":"Federici","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1490-6041","authenticated-orcid":false,"given":"Raffaella","family":"Buzzetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2385-9160","authenticated-orcid":false,"given":"Riccardo","family":"Candido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8787-8286","authenticated-orcid":false,"given":"Salvatore","family":"De Cosmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2948-6257","authenticated-orcid":false,"given":"Angela","family":"Pirillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4565-3131","authenticated-orcid":false,"given":"Giuseppina","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1618-7688","authenticated-orcid":false,"given":"Giorgio","family":"Sesti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1177-0516","authenticated-orcid":false,"given":"Angelo","family":"Avogaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,3]]},"reference":[{"key":"3185_CR1","doi-asserted-by":"crossref","unstructured":"Genitsaridi I, Salpea P, Salim A, Sajjadi SF, Tomic D, James S, Thirunavukkarasu S, Issaka A, Chen L, Basit A et al: 11th edition of the IDF Diabetes Atlas: global, regional, and national diabetes prevalence estimates for 2024 and projections for 2050. Lancet Diabetes Endocrinol. 2026, 14(2):149-156.","DOI":"10.1016\/S2213-8587(25)00299-2"},{"key":"3185_CR2","doi-asserted-by":"publisher","first-page":"112277","DOI":"10.1016\/j.diabres.2025.112277","volume":"225","author":"GD Ogle","year":"2025","unstructured":"Ogle GD, Wang F, Haynes A, Gregory GA, King TW, Deng K, et al. Global type 1 diabetes prevalence, incidence, and mortality estimates 2025: results from the International Diabetes Federation Atlas, 11th edition, and the T1D Index version 3.0. Diabetes Res Clin Pract. 2025;225:112277.","journal-title":"Diabetes Res Clin Pract"},{"issue":"14","key":"3185_CR3","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1001\/jama.2023.4063","volume":"329","author":"JB Echouffo-Tcheugui","year":"2023","unstructured":"Echouffo-Tcheugui JB, Perreault L, Ji L, Dagogo-Jack S. Diagnosis and management of Prediabetes: a review. JAMA. 2023;329(14):1206\u201316.","journal-title":"JAMA"},{"issue":"39","key":"3185_CR4","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","volume":"44","author":"N Marx","year":"2023","unstructured":"Marx N, Federici M, Schutt K, Muller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043\u2013140.","journal-title":"Eur Heart J"},{"issue":"Supplement_1","key":"3185_CR5","doi-asserted-by":"publisher","first-page":"S216","DOI":"10.2337\/dc26-S010","volume":"49","author":"American Diabetes Association Professional Practice Committee for Diabetes","year":"2026","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes. 10. Cardiovascular disease and risk management: standards of care in Diabetes-2026. Diabetes Care. 2026;49(Supplement_1):S216\u201345.","journal-title":"Diabetes Care"},{"key":"3185_CR6","doi-asserted-by":"crossref","unstructured":"Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E et al: Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010;375(9733):2215\u20132222.","DOI":"10.1016\/S0140-6736(10)60484-9"},{"issue":"6","key":"3185_CR7","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1111\/dom.13243","volume":"20","author":"K Khunti","year":"2018","unstructured":"Khunti K, Kosiborod M, Ray KK. Legacy benefits of blood glucose, blood pressure and lipid control in individuals with diabetes and cardiovascular disease: time to overcome multifactorial therapeutic inertia? Diabetes Obes Metab. 2018;20(6):1337\u201341.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"3185_CR8","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1007\/s00125-015-3525-8","volume":"58","author":"B Verges","year":"2015","unstructured":"Verges B. Pathophysiology of diabetic dyslipidaemia: where are we? Diabetologia. 2015;58(5):886\u201399.","journal-title":"Diabetologia"},{"issue":"6","key":"3185_CR9","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.tem.2020.01.015","volume":"31","author":"B Verges","year":"2020","unstructured":"Verges B. Dyslipidemia in Type 1 diabetes: a masked danger. Trends Endocrinol Metab. 2020;31(6):422\u201334.","journal-title":"Trends Endocrinol Metab"},{"issue":"5","key":"3185_CR10","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.diabet.2009.04.004","volume":"35","author":"B Verges","year":"2009","unstructured":"Verges B. Lipid disorders in type 1 diabetes. Diabetes Metab. 2009;35(5):353\u201360.","journal-title":"Diabetes Metab"},{"key":"3185_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11112897","author":"J Vekic","year":"2023","unstructured":"Vekic J, Stromsnes K, Mazzalai S, Zeljkovic A, Rizzo M, Gambini J. Oxidative stress, atherogenic dyslipidemia, and cardiovascular risk. Biomedicines. 2023. https:\/\/doi.org\/10.3390\/biomedicines11112897.","journal-title":"Biomedicines"},{"issue":"2_suppl","key":"3185_CR12","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1177\/2047487319878371","volume":"26","author":"E Dal Canto","year":"2019","unstructured":"Dal Canto E, Ceriello A, Ryden L, Ferrini M, Hansen TB, Schnell O, et al. Diabetes as a cardiovascular risk factor: an overview of global trends of macro and micro vascular complications. Eur J Prev Cardiol. 2019;26(2_suppl):25\u201332.","journal-title":"Eur J Prev Cardiol"},{"issue":"3","key":"3185_CR13","doi-asserted-by":"publisher","first-page":"416","DOI":"10.2337\/dc08-1775","volume":"32","author":"J Guy","year":"2009","unstructured":"Guy J, Ogden L, Wadwa RP, Hamman RF, Mayer-Davis EJ, Liese AD, et al. Lipid and lipoprotein profiles in youth with and without type 1 diabetes: the SEARCH for Diabetes in Youth case-control study. Diabetes Care. 2009;32(3):416\u201320.","journal-title":"Diabetes Care"},{"issue":"8","key":"3185_CR14","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.2337\/dc20-2816","volume":"44","author":"V Harjutsalo","year":"2021","unstructured":"Harjutsalo V, Barlovic DP, Gordin D, Forsblom C, King G, Groop PH, et al. Presence and determinants of cardiovascular disease and mortality in individuals with Type 1 diabetes of long duration: The FinnDiane 50 Years of diabetes study. Diabetes Care. 2021;44(8):1885\u201393.","journal-title":"Diabetes Care"},{"issue":"5","key":"3185_CR15","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.2337\/db15-1517","volume":"65","author":"Diabetes C, Complications Trial\/Epidemiology of Diabetes I, Complications Research G","year":"2016","unstructured":"Diabetes C, Complications Trial\/Epidemiology of Diabetes I, Complications Research G. Risk factors for cardiovascular disease in Type 1 diabetes. Diabetes. 2016;65(5):1370\u20139.","journal-title":"Diabetes"},{"issue":"16","key":"3185_CR16","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1161\/CIRCULATIONAHA.116.025961","volume":"135","author":"A Rawshani","year":"2017","unstructured":"Rawshani A, Rawshani A, Franzen S, Eliasson B, Svensson AM, Miftaraj M, et al. Range of risk factor levels: control, mortality, and cardiovascular outcomes in Type 1 Diabetes Mellitus. Circulation. 2017;135(16):1522\u201331.","journal-title":"Circulation"},{"issue":"15","key":"3185_CR17","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1056\/NEJMoa1608664","volume":"376","author":"A Rawshani","year":"2017","unstructured":"Rawshani A, Rawshani A, Franzen S, Eliasson B, Svensson AM, Miftaraj M, et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med. 2017;376(15):1407\u201318.","journal-title":"N Engl J Med"},{"issue":"10","key":"3185_CR18","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/S2213-8587(18)30035-4","volume":"6","author":"P Bjornstad","year":"2018","unstructured":"Bjornstad P, Donaghue KC, Maahs DM. Macrovascular disease and risk factors in youth with type 1 diabetes: time to be more attentive to treatment? Lancet Diabetes Endocrinol. 2018;6(10):809\u201320.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"24","key":"3185_CR19","doi-asserted-by":"publisher","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","volume":"73","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines. J Am Coll Cardiol. 2019;73(24):e285\u2013350.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"3185_CR20","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u201388.","journal-title":"Eur Heart J"},{"issue":"42","key":"3185_CR21","doi-asserted-by":"publisher","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","volume":"46","author":"F Mach","year":"2025","unstructured":"Mach F, Koskinas KC, Roeters van Lennep JE, Tokgozoglu L, Badimon L, Baigent C, et al. 2025 focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2025;46(42):4359\u201378.","journal-title":"Eur Heart J"},{"issue":"9607","key":"3185_CR22","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","volume":"371","author":"PM Kearney","year":"2008","unstructured":"Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371(9607):117\u201325.","journal-title":"Lancet"},{"issue":"5","key":"3185_CR23","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/S2213-8587(24)00040-8","volume":"12","author":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration","year":"2024","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration, Cholesterol Treatment Trialists\u2019 (CTT) Collaboration. Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis. Lancet Diabetes Endocrinol. 2024;12(5):306\u201319 (Electronic address: ctt@ndph.ox.ac.uk;).","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"3185_CR24","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/dom.13537","volume":"21","author":"GA Nichols","year":"2019","unstructured":"Nichols GA, Philip S, Reynolds K, Granowitz CB, Fazio S. Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin-controlled LDL cholesterol. Diabetes Obes Metab. 2019;21(2):366\u201371.","journal-title":"Diabetes Obes Metab"},{"key":"3185_CR25","unstructured":"Feingold KR: Dyslipidemia in Patients with Diabetes. 2023 Dec 4. In: Feingold KR, Adler RA, Ahmed SF, Anawalt B, Blackman MR, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hamilton E, Hofland J, Jan de Beur S, Kalra S, Kaltsas G, Kapoor N, Kim M, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferr\u00e8re B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors.Endotext [Internet]. South Dartmouth (MA); MDText.com, Inc.; 2000-.PMID: 26247092 https:\/\/pubmed.ncbi.nlm.nih.gov\/26247092\/"},{"key":"3185_CR26","doi-asserted-by":"publisher","first-page":"117313","DOI":"10.1016\/j.atherosclerosis.2023.117313","volume":"394","author":"A Chait","year":"2024","unstructured":"Chait A, Eckel RH, Vrablik M, Zambon A. Lipid-lowering in diabetes: an update. Atherosclerosis. 2024;394:117313.","journal-title":"Atherosclerosis"},{"issue":"15","key":"3185_CR27","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1161\/CIRCULATIONAHA.117.030950","volume":"137","author":"RP Giugliano","year":"2018","unstructured":"Giugliano RP, Cannon CP, Blazing MA, Nicolau JC, Corbalan R, Spinar J, et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation. 2018;137(15):1571\u201382.","journal-title":"Circulation"},{"issue":"12","key":"3185_CR28","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/S2213-8587(17)30313-3","volume":"5","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Leiter LA, Wiviott SD, Giugliano RP, Deedwania P, De Ferrari GM, et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5(12):941\u201350.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"3185_CR29","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/S2213-8587(19)30158-5","volume":"7","author":"KK Ray","year":"2019","unstructured":"Ray KK, Colhoun HM, Szarek M, Baccara-Dinet M, Bhatt DL, Bittner VA, et al. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7(8):618\u201328.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"3185_CR30","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S2213-8587(23)00316-9","volume":"12","author":"KK Ray","year":"2024","unstructured":"Ray KK, Nicholls SJ, Li N, Louie MJ, Brennan D, Lincoff AM, et al. Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial. Lancet Diabetes Endocrinol. 2024;12(1):19\u201328.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"3185_CR31","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.2337\/dc25-0942","volume":"48","author":"YM Kang","year":"2025","unstructured":"Kang YM, Giugliano RP, Ran X, Deedwania P, De Ferrari GM, George JT, et al. Cardiovascular outcomes and efficacy of the PCSK9 inhibitor Evolocumab in individuals with type 1 diabetes: insights from the FOURIER trial. Diabetes Care. 2025;48(9):1512\u20136.","journal-title":"Diabetes Care"},{"key":"3185_CR32","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.2147\/DMSO.S294842","volume":"14","author":"AK Das","year":"2021","unstructured":"Das AK, Saboo B, Unnikrishnan AG. Current practices and gaps in management of dyslipidemia in type 2 diabetes mellitus (T2DM) in accordance with American diabetes association (ADA) guidelines: a subset analysis from a real-world, cross-sectional observational study (LEADD Study). Diabetes Metab Syndr Obes Targets Ther. 2021;14:2693\u2013700.","journal-title":"Diabetes Metab Syndr Obes Targets Ther"},{"key":"3185_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2019-000719","author":"C Hero","year":"2020","unstructured":"Hero C, Karlsson SA, Franzen S, Svensson AM, Miftaraj M, Gudbjornsdottir S, et al. Adherence to lipid-lowering therapy and risk for cardiovascular disease and death in type 1 diabetes mellitus: a population-based study from the Swedish national diabetes register. BMJ Open Diabetes Res Care. 2020. https:\/\/doi.org\/10.1136\/bmjdrc-2019-000719.","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"1","key":"3185_CR34","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1194\/jlr.M030528","volume":"54","author":"SL Pinkosky","year":"2013","unstructured":"Pinkosky SL, Filippov S, Srivastava RA, Hanselman JC, Bradshaw CD, Hurley TR, et al. AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism. J Lipid Res. 2013;54(1):134\u201351.","journal-title":"J Lipid Res"},{"key":"3185_CR35","doi-asserted-by":"publisher","first-page":"13457","DOI":"10.1038\/ncomms13457","volume":"7","author":"SL Pinkosky","year":"2016","unstructured":"Pinkosky SL, Newton RS, Day EA, Ford RJ, Lhotak S, Austin RC, et al. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat Commun. 2016;7:13457.","journal-title":"Nat Commun"},{"issue":"7","key":"3185_CR36","doi-asserted-by":"publisher","first-page":"e011662","DOI":"10.1161\/JAHA.118.011662","volume":"8","author":"U Laufs","year":"2019","unstructured":"Laufs U, Banach M, Mancini GBJ, Gaudet D, Bloedon LT, Sterling LR, et al. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance. J Am Heart Assoc. 2019;8(7):e011662.","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"3185_CR37","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1124\/dmd.122.001142","volume":"51","author":"BM Amore","year":"2023","unstructured":"Amore BM, Cramer C, MacDougall D, Emery MG. The disposition and metabolism of bempedoic acid, a potent inhibitor of ATP citrate lyase, in healthy human subjects. Drug Metab Dispos. 2023;51(5):599\u2013609.","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"3185_CR38","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s10557-021-07147-5","volume":"35","author":"CM Ballantyne","year":"2021","unstructured":"Ballantyne CM, Bays H, Catapano AL, Goldberg A, Ray KK, Saseen JJ. Role of bempedoic acid in clinical practice. Cardiovasc Drugs Ther. 2021;35(4):853\u201364.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"1","key":"3185_CR39","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.cmet.2024.10.014","volume":"37","author":"JY Liu","year":"2025","unstructured":"Liu JY, Kuna RS, Pinheiro LV, Nguyen PTT, Welles JE, Drummond JM, et al. Bempedoic acid suppresses diet-induced hepatic steatosis independently of ATP-citrate lyase. Cell Metab. 2025;37(1):239-254 e237.","journal-title":"Cell Metab"},{"key":"3185_CR40","doi-asserted-by":"crossref","unstructured":"Papa C, Rose A, Martin HNG, Useini A, Geier F, Liao L, Rodriguez-Aguilera JR, Valina-Allo P, Hoffmann A, Tvardovskiy A et al: Bempedoic acid directly binds and activates PPARalpha. Cell Metab 2026;38(4):824-830.e5","DOI":"10.1016\/j.cmet.2025.12.018"},{"issue":"10","key":"3185_CR41","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1016\/j.cgh.2024.03.006","volume":"22","author":"ZM Younossi","year":"2024","unstructured":"Younossi ZM, Golabi P, Price JK, Owrangi S, Gundu-Rao N, Satchi R, et al. The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes. Clin Gastroenterol Hepatol. 2024;22(10):1999-2010 e1998.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"3185_CR42","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/j.cgh.2024.09.038","volume":"23","author":"M Souza","year":"2025","unstructured":"Souza M, Al-Sharif L, Khalil SM, Villela-Nogueira CA, Mantovani A. Global epidemiology and characteristics of metabolic dysfunction-associated steatotic liver disease in type 1 diabetes mellitus: an updated systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2025;23(8):1308-1319 e1317.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"3185_CR43","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1001\/jamacardio.2020.2314","volume":"5","author":"M Banach","year":"2020","unstructured":"Banach M, Duell PB, Gotto AM Jr., Laufs U, Leiter LA, Mancini GBJ, et al. Association of bempedoic acid administration with atherogenic lipid levels in Phase 3 randomized clinical trials of patients with hypercholesterolemia. JAMA Cardiol. 2020;5(10):1124\u201335.","journal-title":"JAMA Cardiol"},{"issue":"6","key":"3185_CR44","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1177\/2047487319864671","volume":"27","author":"CM Ballantyne","year":"2020","unstructured":"Ballantyne CM, Laufs U, Ray KK, Leiter LA, Bays HE, Goldberg AC, et al. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. Eur J Prev Cardiol. 2020;27(6):593\u2013603.","journal-title":"Eur J Prev Cardiol"},{"key":"3185_CR45","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.atherosclerosis.2018.06.002","volume":"277","author":"CM Ballantyne","year":"2018","unstructured":"Ballantyne CM, Banach M, Mancini GBJ, Lepor NE, Hanselman JC, Zhao X, et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study. Atherosclerosis. 2018;277:195\u2013203.","journal-title":"Atherosclerosis"},{"key":"3185_CR46","doi-asserted-by":"publisher","first-page":"117182","DOI":"10.1016\/j.atherosclerosis.2023.06.973","volume":"378","author":"MD Shapiro","year":"2023","unstructured":"Shapiro MD, Taub PR, Louie MJ, Lei L, Ballantyne CM. Efficacy and safety of bempedoic acid in patients with and without metabolic syndrome: pooled analysis of data from four phase 3 clinical trials. Atherosclerosis. 2023;378:117182.","journal-title":"Atherosclerosis"},{"issue":"15","key":"3185_CR47","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","volume":"388","author":"SE Nissen","year":"2023","unstructured":"Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med. 2023;388(15):1353\u201364.","journal-title":"N Engl J Med"},{"issue":"1","key":"3185_CR48","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1186\/s12933-023-02022-z","volume":"22","author":"O De Filippo","year":"2023","unstructured":"De Filippo O, D\u2019Ascenzo F, Iannaccone M, Bertaina M, Leone A, Borzillo I, et al. Safety and efficacy of bempedoic acid: a systematic review and meta-analysis of randomised controlled trials. Cardiovasc Diabetol. 2023;22(1):324.","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"3185_CR49","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1111\/dom.14645","volume":"24","author":"LA Leiter","year":"2022","unstructured":"Leiter LA, Banach M, Catapano AL, Duell PB, Gotto AM Jr., Laufs U, et al. Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: a post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials. Diabetes Obes Metab. 2022;24(5):868\u201380.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"3185_CR50","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1016\/j.jacl.2023.10.011","volume":"18","author":"HE Bays","year":"2024","unstructured":"Bays HE, Bloedon LT, Lin G, Powell HA, Louie MJ, Nicholls SJ, et al. Safety of bempedoic acid in patients at high cardiovascular risk and with statin intolerance. J Clin Lipidol. 2024;18(1):e59\u201369.","journal-title":"J Clin Lipidol"},{"issue":"8","key":"3185_CR51","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s40264-020-00931-6","volume":"43","author":"AFG Cicero","year":"2020","unstructured":"Cicero AFG, Pontremoli R, Fogacci F, Viazzi F, Borghi C. Effect of bempedoic acid on serum uric acid and related outcomes: a systematic review and meta-analysis of the available Phase 2 and Phase 3 clinical studies. Drug Saf. 2020;43(8):727\u201336.","journal-title":"Drug Saf"},{"key":"3185_CR52","doi-asserted-by":"publisher","first-page":"1234601","DOI":"10.3389\/fcvm.2023.1234601","volume":"10","author":"A Alunno","year":"2023","unstructured":"Alunno A, Carubbi F, Campanozzi E, Bellisario F, Schoones JW, Mariani FM, et al. Untangling the relationship between bempedoic acid and gout: results from a systematic literature review. Front Cardiovasc Med. 2023;10:1234601.","journal-title":"Front Cardiovasc Med"},{"key":"3185_CR53","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf784.4295","author":"KK Ray","year":"2025","unstructured":"Ray KK, Nicholls SJ, Lincoff AM, Powell HA, Li N, Bloedon L, et al. Frequency of gout adverse events with bempedoic acid or placebo in those receiving uric acid lowering therapies as prophylaxis or treatment after a gout episode - insights from CLEAR outcomes. Eur Heart J. 2025. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf784.4295.","journal-title":"Eur Heart J"},{"issue":"11 Pt 1","key":"3185_CR54","doi-asserted-by":"publisher","first-page":"102207","DOI":"10.1016\/j.jacadv.2025.102207","volume":"4","author":"KK Ray","year":"2025","unstructured":"Ray KK, Nicholls SJ, Lincoff AM, Li N, Powell HA, Herout PM, et al. Association of uric acid-lowering therapies on gout frequency with bempedoic acid: clinical insights from CLEAR Outcomes. JACC Adv. 2025;4(11 Pt 1):102207.","journal-title":"JACC Adv"},{"issue":"1","key":"3185_CR55","doi-asserted-by":"publisher","first-page":"e000134","DOI":"10.1136\/bmjmed-2022-000134","volume":"1","author":"Y Wang","year":"2022","unstructured":"Wang Y, Zhan S, Du H, Li J, Khan SU, Aertgeerts B, et al. Safety of ezetimibe in lipid-lowering treatment: systematic review and meta-analysis of randomised controlled trials and cohort studies. BMJ Med. 2022;1(1):e000134.","journal-title":"BMJ Med"},{"issue":"3","key":"3185_CR56","first-page":"117","volume":"33","author":"W Masson","year":"2021","unstructured":"Masson W, Lobo M, Lavalle-Cobo A, Molinero G. Effect of bempedoic acid on atherogenic lipids and inflammation: a meta-analysis. Clin Investig Arterioscler. 2021;33(3):117\u201326.","journal-title":"Clin Investig Arterioscler"},{"key":"3185_CR57","unstructured":"Mensah GA, Arnold N, Prabhu SD, Ridker PM, Welty FK: Inflammation and Cardiovascular Disease: 2025 ACC Scientific Statement: A Report of the American College of Cardiology. J Am Coll Cardiol. 2025;S0735-1097(25)07555-2."},{"key":"3185_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2023.03.020","volume":"373","author":"ESG Stroes","year":"2023","unstructured":"Stroes ESG, Bays HE, Banach M, Catapano AL, Duell PB, Laufs U, et al. Bempedoic acid lowers high-sensitivity C-reactive protein and low-density lipoprotein cholesterol: analysis of pooled data from four phase 3 clinical trials. Atherosclerosis. 2023;373:1\u20139.","journal-title":"Atherosclerosis"},{"issue":"1","key":"3185_CR59","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1161\/CIRCULATIONAHA.123.066213","volume":"149","author":"PM Ridker","year":"2024","unstructured":"Ridker PM, Lei L, Louie MJ, Haddad T, Nicholls SJ, Lincoff AM, et al. Inflammation and cholesterol as predictors of cardiovascular events among 13 970 contemporary high-risk patients with statin intolerance. Circulation. 2024;149(1):28\u201335.","journal-title":"Circulation"},{"issue":"6","key":"3185_CR60","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.cmet.2022.05.004","volume":"34","author":"MR Morrow","year":"2022","unstructured":"Morrow MR, Batchuluun B, Wu J, Ahmadi E, Leroux JM, Mohammadi-Shemirani P, et al. Inhibition of ATP-citrate lyase improves NASH, liver fibrosis, and dyslipidemia. Cell Metab. 2022;34(6):919-936 e918.","journal-title":"Cell Metab"},{"issue":"1","key":"3185_CR61","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1186\/s12967-023-04431-w","volume":"21","author":"P Convertini","year":"2023","unstructured":"Convertini P, Santarsiero A, Todisco S, Gilio M, Palazzo D, Pappalardo I, et al. ACLY as a modulator of liver cell functions and its role in metabolic dysfunction-associated steatohepatitis. J Transl Med. 2023;21(1):568.","journal-title":"J Transl Med"},{"issue":"1","key":"3185_CR62","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa042378","volume":"352","author":"PM Ridker","year":"2005","unstructured":"Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352(1):20\u20138.","journal-title":"N Engl J Med"},{"key":"3185_CR63","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.atherosclerosis.2020.12.023","volume":"320","author":"J Rubino","year":"2021","unstructured":"Rubino J, MacDougall DE, Sterling LR, Hanselman JC, Nicholls SJ. Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: a randomized clinical trial. Atherosclerosis. 2021;320:122\u20138.","journal-title":"Atherosclerosis"},{"key":"3185_CR64","unstructured":"Epling D, Crass R, Smith B, Chapel S, Kerschnitzki M, Sasiela W, Louie M, Emery M, Amore B: Dose-response model predictions of the pharmacodynamics effect of bempedoic acid, a competitive inhibitor of ATP citrate lyase, in combination with ezetimibe and statins. Clin Pharmacol Ther. 2023;113(Suppl 1):Abstract PI-057. Presented at: ASCPT 2023 Annual Meeting. March 22\u201324, 2023; Atlanta, GA, USA."},{"issue":"5","key":"3185_CR65","doi-asserted-by":"publisher","first-page":"e867","DOI":"10.1016\/j.jacl.2024.06.001","volume":"18","author":"K Mahajan","year":"2024","unstructured":"Mahajan K, Puri R, Duell PB, Dutta D, Yadav R, Kumar S, et al. Rapid achievement of low-density lipoprotein cholesterol goals within 1 month after acute coronary syndrome during combination therapy with rosuvastatin, ezetimibe and bempedoic acid: initial experience from the LAI-REACT study. J Clin Lipidol. 2024;18(5):e867\u201372.","journal-title":"J Clin Lipidol"},{"issue":"3","key":"3185_CR66","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1161\/CIRCULATIONAHA.125.075388","volume":"153","author":"S Raposeiras-Roubin","year":"2026","unstructured":"Raposeiras-Roubin S, Abu Assi E, Jimenez Mendez C, Minguez de la Guia E, Perez Rivera JA, Marcos Mangas M, et al. Triple versus dual lipid-lowering therapy in acute coronary syndrome: the ES-BempedACS randomized clinical trial. Circulation. 2026;153(3):140\u20139.","journal-title":"Circulation"},{"key":"3185_CR67","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14061839","author":"V Russo","year":"2025","unstructured":"Russo V, Ratti G, Parrella A, De Falco A, Crisci M, Franco R, et al. Clinical utilization and performance of bempedoic acid in an Italian real-world setting: insight from campania region. J Clin Med. 2025. https:\/\/doi.org\/10.3390\/jcm14061839.","journal-title":"J Clin Med"},{"key":"3185_CR68","doi-asserted-by":"publisher","DOI":"10.3390\/jcdd11090286","author":"G Marazzi","year":"2024","unstructured":"Marazzi G, Caminiti G, Perrone MA, Campolongo G, Cacciotti L, Giamundo DM, et al. Addition of Bempedoic acid to statin-ezetimibe versus statin titration in patients with high cardiovascular risk: a single-centre prospective study. J Cardiovasc Dev Dis. 2024. https:\/\/doi.org\/10.3390\/jcdd11090286.","journal-title":"J Cardiovasc Dev Dis"},{"key":"3185_CR69","doi-asserted-by":"publisher","first-page":"109980","DOI":"10.1016\/j.diabres.2022.109980","volume":"190","author":"JS Neves","year":"2022","unstructured":"Neves JS, Newman C, Bostrom JA, Buysschaert M, Newman JD, Medina JL, et al. Management of dyslipidemia and atherosclerotic cardiovascular risk in prediabetes. Diabetes Res Clin Pract. 2022;190:109980.","journal-title":"Diabetes Res Clin Pract"},{"issue":"28","key":"3185_CR70","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1093\/eurheartj\/ehad260","volume":"44","author":"SCORE2-Diabetes Working Group and the ESC Cardiovascular Risk Collaboration","year":"2023","unstructured":"SCORE2-Diabetes Working Group and the ESC Cardiovascular Risk Collaboration. SCORE2-Diabetes Working Group and the ESC Cardiovascular Risk Collaboration. SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe. Eur Heart J. 2023;44(28):2544\u201356.","journal-title":"Eur Heart J"},{"issue":"3","key":"3185_CR71","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1002\/jcsm.12960","volume":"13","author":"PE Penson","year":"2022","unstructured":"Penson PE, Bruckert E, Marais D, Reiner Z, Pirro M, Sahebkar A, et al. Step-by-step diagnosis and management of the nocebo\/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP). J Cachexia Sarcopenia Muscle. 2022;13(3):1596\u2013622.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"17","key":"3185_CR72","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","volume":"36","author":"ES Stroes","year":"2015","unstructured":"Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, et al. Statin-associated muscle symptoms: impact on statin therapy-European atherosclerosis society consensus panel statement on assessment, aetiology and management. Eur Heart J. 2015;36(17):1012\u201322.","journal-title":"Eur Heart J"},{"issue":"34","key":"3185_CR73","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.1093\/eurheartj\/ehac015","volume":"43","author":"I Bytyci","year":"2022","unstructured":"Bytyci I, Penson PE, Mikhailidis DP, Wong ND, Hernandez AV, Sahebkar A, et al. Prevalence of statin intolerance: a meta-analysis. Eur Heart J. 2022;43(34):3213\u201323.","journal-title":"Eur Heart J"},{"key":"3185_CR74","unstructured":"Agenzia Italiana del Farmaco (AIFA). Riclassificazione del medicinale per uso umano \u00abNilemdo\u00bb (determina n. 20\/2023). Gazzetta Ufficiale della Repubblica Italiana. 2023 Jan 27;22. Available from: https:\/\/www.gazzettaufficiale.it\/eli\/id\/2023\/01\/27\/23A00339\/sg"},{"key":"3185_CR75","unstructured":"Agenzia Italiana del Farmaco (AIFA). Riclassificazione del medicinale per uso umano \u00abNustendi\u00bb (determina n. 21\/2023). Gazzetta Ufficiale della Repubblica Italiana. 2023 Jan 27;22. Available from: https:\/\/www.gazzettaufficiale.it\/eli\/id\/2023\/01\/27\/23A00340\/sg"},{"issue":"11","key":"3185_CR76","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","volume":"380","author":"KK Ray","year":"2019","unstructured":"Ray KK, Bays HE, Catapano AL, Lalwani ND, Bloedon LT, Sterling LR, et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med. 2019;380(11):1022\u201332.","journal-title":"N Engl J Med"},{"issue":"18","key":"3185_CR77","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1001\/jama.2019.16585","volume":"322","author":"AC Goldberg","year":"2019","unstructured":"Goldberg AC, Leiter LA, Stroes ESG, Baum SJ, Hanselman JC, Bloedon LT, et al. Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR Wisdom randomized clinical trial. JAMA. 2019;322(18):1780\u20138.","journal-title":"JAMA"},{"issue":"27","key":"3185_CR78","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1093\/eurheartj\/ehy182","volume":"39","author":"F Mach","year":"2018","unstructured":"Mach F, Ray KK, Wiklund O, Corsini A, Catapano AL, Bruckert E, et al. Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. Eur Heart J. 2018;39(27):2526\u201339.","journal-title":"Eur Heart J"},{"issue":"32","key":"3185_CR79","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European atherosclerosis society consensus panel. Eur Heart J. 2017;38(32):2459\u201372.","journal-title":"Eur Heart J"},{"issue":"10","key":"3185_CR80","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41569-024-01039-5","volume":"21","author":"BA Ference","year":"2024","unstructured":"Ference BA, Braunwald E, Catapano AL. The LDL cumulative exposure hypothesis: evidence and practical applications. Nat Rev Cardiol. 2024;21(10):701\u201316.","journal-title":"Nat Rev Cardiol"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-026-03185-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-026-03185-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-026-03185-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T06:02:12Z","timestamp":1778738532000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12933-026-03185-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,3]]},"references-count":80,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3185"],"URL":"https:\/\/doi.org\/10.1186\/s12933-026-03185-1","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,3]]},"assertion":[{"value":"2 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MF received honoraria for speaker activities, for serving on advisory boards from Daiichi Sankyo, Boehringer Ingelheim, Eli Lilly, Amarin, Amgen, Novo Nordisk, Merck Sharpe and Dohme, Novartis and Sanofi; RB received honoraria for speaker activities, for serving on advisory boards from Daiichi Sankyo, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Merck Sharpe and Dohme, Sanofi, Astrazeneca, Abbott; RC has received grants and consultancy or lecture fees from Abbott, AstraZeneca, Bayer, Boehringer, Lilly, MSD, Menarini Diagnostics, Mundipharma, Novo Nordisk, Roche Diabetes Care, and Sanofi.; SDC has nothing to disclose; AP has nothing to disclose; GR received honoraria as speaker or consultant for Boeringher, Lilly, AstraZeneca, Sanofi, Novo Nordisk, Abbott; GS received honoraria for speaker activities, for serving on advisory boards from Daiichi Sankyo, TEVA, Sanofi, Novo Nordisk and Merck Sharpe and Dohme; AA received honoraria for speaker activities, for serving on advisory boards, or consultancy from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Amarin, Bruno Farmaceutici, Amgen, Novo Nordisk, and Sanofi.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"156"}}